Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, PMID: 31735560
Isatuximab for the treatment of relapsed/refractory multiple myeloma, PMID: 33111607
Isatuximab: First Approval, PMID: 32347476
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design, PMID: 31833394
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab, PMID: 31779273
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma, PMID: 30692097
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells, PMID: 32922390
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study, PMID: 32975869
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma, PMID: 30862646
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis, PMID: 32444867
Isatuximab, PMID: 32697463
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design, PMID: 29268619
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis, PMID: 32586908
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma, PMID: 33080623
Antibodies to watch in 2020, PMID: 31847708
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date, PMID: 32446599
Correction to: Isatuximab: First Approval, PMID: 32447610
Incorporating isatuximab in the treatment of multiple myeloma, PMID: 31735559
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma, PMID: 30926770
Isatuximab: A Review of Its Use in Multiple Myeloma, PMID: 34351561
Immune-based therapies in the management of multiple myeloma, PMID: 32829378
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients, PMID: 33021075
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, PMID: 30858549
CD38 antibodies in multiple myeloma: back to the future, PMID: 29118010
Emerging agents and regimens for multiple myeloma, PMID: 33168044
Antibodies to watch in 2019, PMID: 30516432
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond, PMID: 29257139
Dexamethasone as a partner of isatuximab, PMID: 33661291
Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma, PMID: 32331242
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma, PMID: 32054831
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma, PMID: 28249894
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance, PMID: 30294326
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, PMID: 26864107
Immunomodulatory effects of CD38-targeting antibodies, PMID: 29702148
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma, PMID: 32961764
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma, PMID: 32409691
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma, PMID: 28483761
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, PMID: 34097854
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis, PMID: 33839618
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018, PMID: 31076371
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab, PMID: 31409922
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia, PMID: 34376579
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma, PMID: 34213061
Tafasitamab, PMID: 33355731
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma, PMID: 34185964
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies, PMID: 30498492
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis, PMID: 33432438
Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma, PMID: 34024861
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide, PMID: 26338273
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis, PMID: 34383345
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study., PMID:40530259
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT., PMID:40523501
CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma., PMID:40516447
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma., PMID:40493883
Global Access to Multiple Myeloma Therapies., PMID:40466014
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study., PMID:40459178
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma., PMID:40459097
Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma., PMID:40453054
The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies., PMID:40452474
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma., PMID:40437669
Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)., PMID:40416867
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma., PMID:40387425
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison., PMID:40354013
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region., PMID:40352314
Beyond the Hydrashift assay: the utility of isoelectric focusing for therapeutic antibody and paraprotein detection., PMID:40305408
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system., PMID:40302414
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study., PMID:40284030
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group., PMID:40271095
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials., PMID:40257476
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse., PMID:40241199
Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis., PMID:40176408
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis., PMID:40143674
A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab., PMID:40124649
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of atezolizumab for alveolar soft part sarcoma, epcoritamab for follicular lymphoma, and isatuximab for multiple myeloma in Japan., PMID:40117081
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial., PMID:40109195
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047
Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques., PMID:40088315
How First-Line Therapy is Changing in Transplant-Eligible Multiple Myeloma Patients., PMID:40084095
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma., PMID:40073374
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data., PMID:40045883
Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency., PMID:40045293
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies., PMID:40005973
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma., PMID:40005960
Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma., PMID:40000356
Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis., PMID:39963097
Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region., PMID:39944235
Monoclonal Antibodies and Small-Molecule Inhibitors Associated Osteonecrosis of Jaw: A Retrospective Pharmacovigilance Study., PMID:39922223
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial., PMID:39909655
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study., PMID:39898517
Isatuximab-Based Therapy for Multiple Myeloma. Reply., PMID:39879605
Isatuximab-Based Therapy for Multiple Myeloma., PMID:39879604
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma., PMID:39851267
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis., PMID:39847579
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial., PMID:39841461
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies., PMID:39774926
Isatuximab (Sarclisa) for multiple myeloma., PMID:39752726
Advancements in the Treatment of Multiple Myeloma., PMID:39744254
Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials., PMID:39738354
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan., PMID:39729222
For research use only. Not for human or drug use.
